February is Heart Month, a time to raise awareness on cardiovascular health. Cardiac safety issues are one of the main reasons promising drugs are halted in development.

With the collaboration of a number of leading core ECG vendors and our in-house clinical units specially designed for assessing cardiac safety, Altasciences has designed and conducted over 30 early cardiac safety and QT prolongation studies.

Whether you choose to conduct your cardiac assessment trials earlier (such as in first-in-human studies) or a little later (after completing Phase II), you can benefit from the following advantages:

In this issue of The Altascientist, we discuss the ICH regulations, and provide a thorough review of the design and timing of QT studies for your drug development program.

Included is a recent case study on the QT assessment in a novel cannabis trial involving 80 subjects.

It's animal welfare month at Altasciences!

Through the course of your regulatory required preclinical research, Altasciences considers the humane and appropriate care of all animals a high priority. Our team is dedicated to animal welfare and environmental enrichment, and understands the importance of compassion, sensitivity, and adherence to regulatory guidelines.

Learn more on our animal welfare and C.A.R.E. programs

Discover our preclinical solutions

Speak with our experts, or better yet, come for a visit.

Renowned for our full-service offering, we often get asked — how does Altasciences manage the development process for biologics and biosimilars so seamlessly from the required preclinical studies to first-in-human trials?